世界の製薬ビジネスを伝える「Scrip」と、各国で変化する製薬関連の規制に特化した「Pink Sheet」。普段は英語で発信する2つのオンラインメディアから、今注目の話題を日本語で短くまとめてお届けします。

今回取り上げた記事はこちら 「Chinese Biotechs Ascend Deal-Making By Partnering Up Claudin 18.2 Agents（邦題意訳：中国バイオテック企業が急成長　CLDN18.2抗体で協業続々）」

https://scrip.pharmaintelligence.informa.com/SC147989/Chinese-Biotechs-Ascend-DealMaking-By-Partnering-Up-Claudin-182-Agents

世界の製薬業界ニュース Scrip（スクリップ）とは？
https://www.citeline.com/ja-jp/products-services/commercialization/scrip

Voice Recorder

【3分で解説  世界のファーマ】第9回 中国企業が急成長 CLDN18.2抗体市場のいま (Japanese-language podcast)

Jade and Keia welcome Tenile Pritchard to the Kitchen Table to share her story of survival and self advocacy after being diagnosed with colon cancer at 38 years old. Listen to this important conversation and share it with your loved ones.

---

Support the Show:

Everyone’s got their own Mickey D’s moments. Go on and make more delicious memories

---

Keep up with Jade & Keia across your favorite social media platforms.

https://gettingrown.co/
https://www.patreon.com/gettingrown
Email: GettinGrownPodcast@gmail.com
Twitter: @GettinGrownPod
IG: @GettinGrownPod
https://gettingrown.co/

Surviving Scary Things (Feat: Tenile Pritchard )

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Diego Raimondo and Giulia Rovero. 

Dr. Raimondo works as medical director and assistant researcher at the Division of Gynecology and Pathophysiology of Human Reproduction, Bologna, Italy, directed by Prof. Renato Seracchioli. He received his PhD on new technologies for endometriosis surgical removal from the University of Bologna in 2021. He is an Advisory Board Member of the ESGE (European Society for Gynaecological Endoscopy) and member of the Special Interest Group in Robotics. His research interests are focused on minimally invasive surgery (laparoscopic, robotic and hysteroscopic) for endometriosis and endometrial cancer. 

Dr. Giulia Rovero graduated in Medicine in 2017 at the University of Florence. She is currently a fifth-year resident at the Division of Gynecology and Pathophysiology of Human Reproduction, Bologna, Italy, directed by Prof. Renato Seracchioli. In 2022/23 she spent twelve months at the Lariboisiere Hospital in Paris focusing on gynecologic oncology. She is developing her research activity in collaboration with Dr. Raimondo in the field of minimally invasive surgery for endometrial cancer. 

Highlights:

* In endometrial carcinoma (EC) patients, the rate of sentinel lymph node (SLN) mapping failure ranges from 20% to 25%.
* Pooled data assessing predictive factors of SLN mapping failure in EC patients undergoing SLN biopsy through the cervical injection of indocyanine green (ICG) are lacking.
* ICG dose <3mL, advanced FIGO stage, lymph node involvement and bulky lymph node are predictive factors of SLN mapping failure in EC patients.
* Neither clinical features (i.e., BMI >30 kg/m2, menopausal status, adenomyosis) nor surgical history is significantly associated with SLN mapping failure in EC patients.
* Deep myometrial invasion, FIGO grade 3, non-endometrioid histotype, and lymphovascular space invasion are not significantly associated with SLN mapping failure in EC patients.

Predictors of SLN Mapping Failure with Diego Raimondo and Giulia Rovero

This week, Dr Marilena Giannoudi focuses on the geriatric career path with Dr Kat Ralston. This episode covers the day-to-day as well as the advantages, challenges, and the pathway to this profession. Dr Ralston provides many resources to inform your journey into geriatric medicine and discusses a few interesting cases she has encountered. 

Dr Kat Ralston is a geriatric medicine registrar in Edinburgh. She is also the Education Co-Vice Chair and the joint Podcast Lead for the RCPE Trainee & Members' Committee (T&MC).

Dr Marilena Giannoudi is a cardiology registrar based in Leeds. She is Co-Chair of the Trainees and Members’ Committee, a Fellow of the Higher Education Academy, and is currently undertaking a PhD.

--Useful Links--
Physician Higher Specialty Training Recruitment - https://www.phstrecruitment.org.uk/specialties/geriatric-medicine

British Geriatrics Society
https://www.bgs.org.uk/

Clinical Frailty Scale - 
https://www.bgs.org.uk/sites/default/files/content/attachment/2018-07-05/rockwood_cfs.pdf

REDMAP Framework
https://www.spict.org.uk/red-map/

Think Delirium Toolkit
https://learn.nes.nhs.scot/2442/rrheal/education-networks/rural-teams-education-network/think-delirium-improving-the-care-for-older-people-delirium-toolkit

The Geriatric 5M’s
https://agsjournals.onlinelibrary.wiley.com/doi/10.1111/jgs.14979

Silver Book II
Geriatric Syndromes (British Geriatrics Society) - https://www.bgs.org.uk/resources/silver-book-ii-geriatric-syndromes

ACB Calculator
https://www.acbcalc.com/

-- Related episodes --

A Fresh Look at the Geriatric Giants – Front Door and Beyond, Clinical Conversations Podcast
https://podcasts.rcpe.ac.uk/show/clinical-conversations/a-fresh-look-at-the-geriatric-giants-front-door-and-beyond-26-feb-2024

Frailty for the Non-Specialist, Clinical Conversations Podcast 
https://podcasts.rcpe.ac.uk/show/clinical-conversations/frailty-for-the-non-specialist-11-mar-2024

Recording Date: 02 April 2024

Choose RCPE as your College of Entry for PACES -- 
We encourage you to sit PACES with our College. We have a friendly and experienced examinations team who expertly support candidates, and we deliver PACES at centres across the UK. Select RCPE as your College of Entry when applying online through your My MRCP(UK) online account.

-- Follow us --
www.instagram.com/rcpedintrainees
twitter.com/RCPEdinTrainees

-- Upcoming RCPE Events --
events.rcpe.ac.uk/

Feedback: cme@rcpe.ac.uk

Career Conversations

Medical Specialties - Geriatric Medicine (4 Dec 2024)

Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics, discussed the company’s mission to harness the powerful complement system for the treatment of serious diseases.

“Powerful Yet Unexplored”: Commit Biologics Tackles The Complement System

This episode, 'Translating Promising Drug Candidates from Preclinical Screening to Clinical Trials,' will explore the challenges and successes of moving promising drug candidates from preclinical screening to clinical trials in oncology.

Join Dr. Steve Shnyder, Associate Professor at the Institute of Cancer Therapeutics, University of Bradford, as he explores:

- The unique challenges in oncology drug development.
- Preclinical model limitations and needed innovations.
- Translating preclinical insights into effective clinical trial design.
- The role of AI and machine learning in overcoming development hurdles.
- Real-world case studies of successful oncology drug approvals.



ranslating Promising Drug Candidates from Preclinical Screening to Clinical Trials

Liver cancer, especially hepatocellular carcinoma (HCC), remains a major health concern worldwide. In Latin America, the situation becomes more difficult due to limited access to advanced treatments and the high prevalence of underlying liver diseases. A recent research paper, published in Volume 16 of Oncotarget by researchers from Argentina, Brazil, Chile, and Colombia, offers valuable insights into how patients in the region respond to a widely used immunotherapy regimen. This real-world study explores both the effectiveness of treatment and the risks of immune-related side effects.

Understanding Hepatocellular Carcinoma: Why It is So Difficult to Treat

Hepatocellular carcinoma is often diagnosed at an advanced stage and frequently occurs in people with pre-existing liver conditions such as cirrhosis. Standard treatments like surgery or local therapies are not always possible in these cases. In recent years, the combination of two drugs—atezolizumab and bevacizumab—has shown promise in extending survival. However, most of the evidence comes from controlled clinical trials that may not represent the realities faced by healthcare providers and patients in Latin America.

The Study: Immunotherapy for Hepatocellular Carcinoma in Latin America

In a multicenter study titled “Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma,” led by Leonardo Gomes da Fonseca from Hospital das Clínicas, Universidade de São Paulo, Brazil, and Federico Piñero from Hospital Universitario Austral, Argentina, researchers aimed to fill that gap. The study included 99 patients with advanced HCC from Argentina, Brazil, Chile, and Colombia. All patients received the combination of atezolizumab and bevacizumab. The main objectives were to assess how frequently immune-related side effects, known as immune-related adverse events (irAEs), occurred and whether these events affected overall survival.

Full blog - https://www.oncotarget.org/2025/07/02/immunotherapy-safety-for-hepatocellular-carcinoma-in-latin-america-insights-from-a-real-world-study/

Paper DOI - https://doi.org/10.18632/oncotarget.28721

Correspondence to - Federico Piñero - fpinerof@cas.austral.edu.ar

Video short - https://www.youtube.com/watch?v=gk3oQwzIC-E

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28721

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - cancer, liver cancer, immunotherapy, adverse events, immunology, real-world 

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh

MEDIA@IMPACTJOURNALS.COM

Oncotarget

Immunotherapy Safety for Hepatocellular Carcinoma in Latin America: Insights from a Real-World Study

BUFFALO, NY - July 7, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on June 17, 2025, titled “Genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A single institution experience.”

In this study, a research team led by first author Fei Fei and corresponding author Michelle Afkhami from the City of Hope Comprehensive Cancer Center investigated a rare and aggressive type of blood cancer called blastic plasmacytoid dendritic cell neoplasm (BPDCN). Their research uncovered frequent mutations in key genes and identified CCDC50 as a potential biomarker for diagnosis and disease monitoring. These findings could help improve how this cancer is detected and treated in the future.

BPDCN most often affects older adults and is known for its rapid progression and poor survival rates. The researchers performed genetic sequencing on 21 patients to better understand the disease. They found that two genes, TET2 and ASXL1, were frequently mutated in these patients and were linked to worse survival, especially in those over 65 years old.

“Our study revealed that TET2 (57%) and ASXL1 (33%) were the most frequently mutated genes, followed by NRAS (29%), SRSF2 (14%), ZRSR2 (14%), and KMT2D (14%).”

The study also discovered that a gene called CCDC50 was expressed at much higher levels in BPDCN samples compared to other blood cancers, such as acute myeloid leukemia and chronic monomyelocytic leukemia. This suggests that CCDC50 may help clinicians distinguish BPDCN from other similar diseases. Importantly, CCDC50 levels dropped significantly in patients whose disease went into remission, highlighting its potential as a tool for tracking disease activity over time.

Researchers further observed that patients who received stem cell transplants lived longer than those who did not, reinforcing the importance of this treatment approach. However, BPDCN remains a challenging disease with an overall poor outlook, making these findings an important step toward better care.

This research provides new insights into the genetic changes behind BPDCN and points to CCDC50 as a promising marker to improve diagnosis and monitor treatment success. Larger studies will be needed to confirm these results and bring these discoveries closer to use in routine medical practice.

DOI - https://doi.org/10.18632/oncotarget.28742

Correspondence to - Michelle Afkhami - mafkhami@coh.org

Video short - https://www.youtube.com/watch?v=wUjr3uU3onI

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28742

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - cancer, Blastic plasmacytoid dendritic cell neoplasm (BPDCN), Next-generation sequencing (NGS), CCDC50

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh

MEDIA@IMPACTJOURNALS.COM

Key Genetic Alterations and Biomarker for Blastic Plasmacytoid Dendritic Cell Neoplasm

On this episode, we are joined by Joran Miller, PharmD to discuss treatment options for mantle cell lymphoma. Dr. Miller is a Hematology Oncology clinical pharmacy specialist at UNC Chapel Hill.

Podcast Ep 9: Mantle Cell Lymphoma (ft. Dr Jordan Miller)

IASLC CEO Dave Mesko sits down with IASLC President-Elect candidate, Dr. Heather Wakelee, Professor of Medicine, Oncology at Stanford University in Stanford, California. Voting is available to active IASLC members and ends at 11:59 Eastern Time on June 26, 2019. Vote at directvote.net/IASLC.

IASLC President-Elect Elections: Introducing Candidate Dr. Heather Wakelee

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.

RCPE's Podcast Series 'Career Conversations' by the Trainees & Members' Committee (T&MC).

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.

Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/

Keia and Jade are two happy and hard working (Blackity) Black Women who are just trying to learn how to adult, for real.  

Join us each week for Kitchen TableTalk, Petty Peeves and Lessons in Black Women Self Care, as we try to figure out life as 30-somethings.

Evidence-based medicine and drug updates for pharmacists, physicians, NPs, PA-Cs, and students that are on the go.

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

Lung Cancer considered is funded in part by AstraZeneca, Daiichi Sankyo, Inc., and Takeda

Popular tracks tagged #oncology